Stop Cuts to Education, Screening & Surveillance Programs The President’s proposed budget for Fiscal Year 2026 would eliminate the CDC’s Division of Cancer Prevention and Control (DCPC). This division supports the only federally funded education and screening programs focused on gynecologic cancers. If these cuts move forward, communities across the country will lose: These programs are … Continued
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget Update: Critical Cancer Programs at Risk Congress is deep into its work on the fiscal year 2026 (FY26) appropriations bills, and decisions made now will shape the future of cancer care, prevention, and research. While there is strong bipartisan support for cancer … Continued
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies that support gynecologic cancer patients. Here’s what’s happened over the last month—and what’s next. Budget Update: CDC Cancer Programs at Risk The administration’s proposed FY26 … Continued
A new article from Patient Power highlights findings from a paper authored by Ovarian Cancer Research Alliance (OCRA) and Komodo Health, that reveals significant gaps in genetic testing for ovarian cancer patients. Chad Ramsey, OCRA’s Vice President of Policy, spoke with Patient Power about the study’s results and the urgent need to close these gaps. … Continued
Spring is here—and so is appropriations season in Washington, DC. This month has brought key developments in both the FY26 federal budget process and state-level policy action that could impact gynecologic cancer research, prevention, and patient care. Here’s what advocates need to know: Draft Budget Proposal Would Eliminate Key CDC Cancer Programs A draft of the administration’s … Continued
New administrations inevitably bring changes, both big and small. The top priority of OCRA’s Policy & Advocacy team remains the same—ensuring the voices of the ovarian and gynecologic cancer community are heard and the issues that impact our community are considered. Next month, OCRA’s Advocate Leaders will convene in Washington, DC to once again bring … Continued
In a new article from TheaterMania, ovarian cancer survivor and OCRA Advocate Leader Kristen Jantonio shares how her passion for theater has been a source of strength and inspiration since being diagnosed with ovarian cancer. Through OCRA’s Advocate Leader program, she helps drive policy changes that support the gynecologic cancer community. Learn more in Playhouse Square’s Kristen … Continued
OCRA Joins Forces With Rivkin Center for Ovarian Cancer Research Ovarian Cancer Research Alliance (OCRA) has announced that the Rivkin Center for Ovarian Cancer Research will join with OCRA effective April 1, 2025. This historic collaboration unites two respected organizations committed to advancing research for a cure for ovarian and all gynecologic cancers. “OCRA has always … Continued
Happy New Year from OCRA’s Policy and Advocacy Team! As we step into a new year, we want to take a moment to thank you for your unwavering support and dedication. Each year brings fresh opportunities to drive meaningful change for the ovarian and gynecologic cancer community, and we couldn’t do it without you. Update … Continued
As we close out 2024, we at OCRA are reflecting on a year of powerful advocacy and immense gratitude. Your passion and commitment to raising awareness, driving policy change, and pushing for progress for the ovarian and gynecologic cancer community have left a mark that will be felt for years to come. Here are some … Continued
“To improve patient outcomes – and quality of life – we must minimize roadblocks for access to cancer screenings that could change the course of a diagnosis. The time is now. We are urging Congressional action this week to enact this legislation into law.” The Ovarian Cancer Research Alliance today released the following statement regarding … Continued
OCRA recently joined the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT), which is working to ensure genetic testing access for all who may carry inherited mutations that increase the risk of ovarian and other cancers. The coalition, which includes patient advocacy and industry members, endeavors to drive changes in cancer-related genetic testing policies to expand … Continued
Get email updates about research news, action alerts, and ways to join the fight.
